Home
overview

SMi’s 3rd Annual Conference
3D Cell Culture
February 20-21, 2019 | London, United Kingdom
-------------------------------------------------------------------------
Cell Culture in an important tool for research and development within the life science industry. Over the past few years, 3D Cell Culture has gained momentum within the pharmaceutical industry due to the benefits that this model offers over conventional cell culture methods. 3D cell culture enables cells to grow and interact with their surroundings in all three dimensions, better mimicking the in-vivo conditions in which the cells are naturally present. This enhances the ability for scientists to study basic biological mechanisms such as cell number monitoring, cell viability, proliferation and morphology. 3D cell cultures also have greater stability and longer life spans.

Researchers globally are realizing the potential of 3D cell culture for various applications, including testing and discovering new drugs to treat cancer, organ-on-chip models to study the human physiology in an organ specific context, and 3D cell printing to produce organ models. Therefore, this market is likely to grow over the next few years and is in fact projected to reach USD 1.7 Million by 2022, growing at a CAGR of 20.3% between 2017-2022. Growth in this market is also driven by global factors such as a need for alternative methods to animal resting, funding from governments and private entities and technological advancements in the field.

Join us in February 2019, as we look at the latest developments in the 3D Cell Culture field. Network with industry experts, gain insight into how the pharmaceutical industry is utilizing 3D Cell Culture technologies to enhance research and development, discuss the potential for novel in-vitro cell culture models to replace animal models, and discover novel 3D cell culture systems, organ-on-chip, 3D imaging of organoids and other technologies in development.
 

 

 

The 3D Cell Culture field is rapidly evolving. Each year, new technologies are being developed, promoting exponential growth and development within the industry. Developing on last years’ success, this must-attend conference will bring together industry experts to discuss and analyze the latest advancement and challenges within 3D Cell Culture.

At SMi’s 3rd Annual 3D Cell Culture Conference, you will gain insight into:

  • Organ-on-chip technologies and their applications in the pharmaceutical industry
  • Panel discussion on whether 3D Cell Culture will replace animal models
  • Determining the predictive validity of 3D models and achieving standardization for preclinical testing
  • Global developments in 3D Cell Culture and how this exponential growth will impact researchers
  • Several novel techniques for imaging of 3D Cell Cultures
  • Development of 3D eye models for early assessment of retinal toxicity 
  • Musculoskeletal regeneration harnessing preclinical models for tissue repair

Aber; Aber Instruments Ltd; Adaptimmune Ltd; Aptuit (Verona) S.r.l; Asterand Bioscience; AstraZeneca; Barts Cancer Institute; Bial; Biogelx Ltd; BioTek Instruments Ltd.; Boehringer-Ingelheim; Cellesce Limited; Cellon S.A; Cellular Dynamics International; Corning; Department of Craniofacial Development and Stem Cell Biology; Durham University; EPISKIN SA; Epithelix; F. Hoffmann-La Roche AG; F. Hoffmann-La Roche Ltd.; GE Healthcare; GlaxoSmithKline; GSK; Hubrecht Institute; Immunocore Ltd; Imperial College; Imperial College London; Jellagen Pty Ltd; Kings College London; King's College London; Kings College School Of Medicine And Dentistry; Lonza Incorporated; Medical Research Council; MHRA; Microduits GmbH; Neem Biotech Ltd; Nexcelom; NIFES; Novartis Institutes For Biomedical Research; Novartis Pharmaceuticals; Pfizer; Plasticell Ltd; ProDigest; Progen Biotechnik GmbH; Reinnervate; Roche Diagnostics ; Samedan Ltd; Sanofi; Sigma Aldrich; Stemtek Therapeutics; tebu-bio; Technologie Servler; The Scripps Research Institute; Thermo Fisher Scientific; TissUse GmbH; Unilever Research Colworth; university surrey; Ventana Medical System, Inc;

Conference programme

8:30 Registration & Coffee

9:00 Chairman's Opening Remarks

Stefan Przyborski

Stefan Przyborski, Proessor of Cell Technology, University of Durham
View Bio

9:10 Development and application of bioengineered models of human tissues in vitro

Stefan Przyborski

Stefan Przyborski, Proessor of Cell Technology, University of Durham
View Bio

  • Novel cell culture technologies are providing new opportunities to bioengineer human tissue constructs in vitro
  • Such tissue equivalent models enable the development of new in vitro assays and assessment of drug activity
  • Building models that more accurately simulate normal tissue structure for R&D use will enhance the predictive accuracy of in vitro assays
  • Here we demonstrate the potential of such technology to create new opportunities for discovery research, drug assessment and safety screening
  • 9:45 Tools, not toys: from innovation to regulatory application

    William Mattes

    William Mattes, Director, Division of Systems Biology, U.S. Food and Drug Administration
    View Bio

  • An incredibly important consideration for any new technology is what decisions will be made by its use
  • The “Context of Use” should guide what information is needed to “validate” a new technology
  • The role of new technologies in regulatory processes can be informed by Biomarker / Drug Development Tool Qualification process developed by FDA and EMA
  • 10:20 Morning Coffee

    10:50 Improving preclinical predictivity with human-based 3D models

    Samuel Jackson

    Samuel Jackson, Programme Manager, Disease Models, NC3Rs
    View Bio

  • The failure of compounds during clinical development has been linked to the poor predictivity of models used for basic research and drug development
  • New technologies are rapidly evolving which enable complex 3D cell culture models to be built with human cells or tissue, and which closely mimic some aspects of human physiology and disease
  • Application of these technologies to basic research and drug development holds the promise of being able to better predict safe or efficacious medicines before clinical trials are initiated
  • In addition, these new ways of working often bring time or money savings, and minimise the reliance on animal models
  • In this talk the principles of implementing the 3Rs with new technology will be illustrated with examples from the NC3Rs and wider research community
  • 11:25 3D cell culture in the advancement of medicines discovery

    Sally  Price

    Sally Price, Head of Cell and Translational Science, Medicines Discovery Catapult

  • The need for 3D models in developing new medicines and current challenges
  • Developments in 3D models that are advancing medicines discovery
  • How the Medicines Discovery Catapult is using 3D cell cultures in collaborative projects
  • Examples/case studies from our work
  • 12:00 Musculoskeletal regeneration harnessing preclinical models for tissue repair

    Richard Oreffo

    Richard Oreffo, Director, Centre for Human Development, University Of Southampton

  • Overview of UKRMP Smart Materials HUB work in the field
  • Development of ex vivo and organotypic models for skeletal tissue repair – a simple screen approach
  • Use of innovative biomaterials in skeletal repair
  • Translation and challenges of skeletal tissue engineering approaches for patient benefit
  • 12:35 Networking Lunch

    13:35 PANEL DISCUSSION: Will 3D Cell Culture replace animal models?

  • Advantages and disadvantages of 3D Cell Culture vs animal models
  • Where are we now; and where do we need to go?
  • Is the technology advanced enough to fully replace animal models?
  • Future of 3D Cell Culture
     
  • Stefan Przyborski

    Stefan Przyborski, Proessor of Cell Technology, University of Durham
    View Bio

    Helena Hogberg

    Helena Hogberg, Deputy Director, Center for Alternatives to Animal Testing, Johns Hopkins University Bloomberg School of Public Health

    Jason Ekert

    Jason Ekert, Head of Complex In Vitro Models, GSK

    14:10 The future of 3D cell culture in medicine: blending medical devices and cells to build organs

    Melanie Matheu

    Melanie Matheu, Founder, CEO , Prellis Biologics

  • Organ and tissue design and development
  • State of the art for 3D Bioprinting
  • Limitations of current systems and methods
  • Pathways to full organ replacement
  • 14:45 Amplification of extracellular matrix via macromolecular crowding in 2D, 3D, cell culture and in bioprinting

    Michael  Raghunath

    Michael Raghunath, Head Center for Cell Biology & Tissue Engineering Director Competence Center TEDD, Zurich University of Applied Sciences
    View Bio

  • The importance of the cellular microenvironment in controlling cell behavior and fate
  • Current highly aqueous culture conditions impair efficient ECM deposition
  • Overcoming this issue by introducing macromolecular crowding (MMC) into the culture medium of monolayer cultures or hydrogels
  • MMC adopted by the pharma industry for antifibrotic screening: production of stem cell matrix, and tuning the microarchitecture of bioprinted collagen hydrogels
  • 15:20 Afternoon Tea

    15:50 Meeting tissue engineering challenges with 4D bioprinting

    Kevin Fournier

    Kevin Fournier, Sales and Applications Manager, Poietis
    View Bio

  • Laser assisted bioprinting
  • 3D bioprinting
  • Tissue engineering
  • 3D in vitro tissue models
     
  • 16:25 3-dimensional imaging of organoids

    Anne Rios

    Anne Rios, Principal Investigator, Princess Maxima Center
    View Bio

  • Protocol of 3D imaging of intact organoids
  • High throughput 3D live imaging and automated quantification
  • In vivo model for human cancer based on organoid technology
  • 17:00 Automated confocal imaging and analysis process for liver-on-a-chip platform

    Akidil Asli

    Akidil Asli, Cell and Molecular Scientist , AstraZeneca
    View Bio

  • Advantages of a liver-on-a-chip platform over traditional 2D models
  • Introduction to automated confocal imaging and analysis process on liver-on-a-chip platform
  • Benefits of using automated imaging and analysis process as a detection method
  • Challenges of optimizing the automated analysis process for the quadruple co-culture liver-on-a-chip platform
  • 17:35 Chairman’s Closing Remarks and Close of Day One

    Stefan Przyborski

    Stefan Przyborski, Proessor of Cell Technology, University of Durham
    View Bio

    8:30 Registration & Coffee

    9:00 Chairman's Opening Remarks

    Nicola Valeri

    Nicola Valeri, Team Leader, The Institute of Cancer Research
    View Bio

    9:10 3D goes clinical – Modified islet transplantation as blueprint for future 3D cell transplantation

    Patrick Kugelmeier

    Patrick Kugelmeier, Director of Science, Kugelmeiers
    View Bio

  • The future operating theatre will be the laboratory
  • 3D cell culture as a prerequisite for future cell transplantation applications
  • Challenges in preparing a clinical trial for cell therapy using the example of modified islet transplantation
  • Consequences for future cell therapies
  • 9:45 Not all 3-D is the same! The development of cell-based assay formats for compound profiling using

    Gary Allenby

    Gary Allenby, Business Development Director and Chief Scientific Officer, Aurelia Bioscience
    View Bio

  • Electrospun fibres have been used to generate a high throughput chemotaxis model for profiling compounds using human derived primary cells in 3-D
  • Electrospun fibres can be used to grow human iPSC derived cortical neurones for profiling of compounds for safety assessement in 3-D
  • Who needs a plate washer – we will show data generated in a number of kinetic cell based binding assays in which we have used electrospun fibre to manipulate cells to improve assay performance
  • Combination of electrospun fibres and 3-D printing – an example of how to generate more complex models of biology in a well plate
  • 10:20 Morning Coffee

    10:50 Developing translationally relevant 3D models for pre-clinical drug development

    Jason Ekert

    Jason Ekert, Head of Complex In Vitro Models, GSK

  • Challenges and opportunities in developing translationally relevant 3D models
  • What components need to be considered when developing human relevant and predictive 3D models?
  • How do we characterize, scale and automate 3D models in preclinical drug discovery?
  • 11:25 Human 3D neuronal models for drug safety assessment

    Stefan Kustermann

    Stefan Kustermann, Lab Head, Roche

  • Presentation of 3D neuronal model of the brain and eye/retina for drug safety testing
  • Application of such models for drug safety testing, current gaps and future opportunities
  • What’s next? Future trends and needs in the field
  • 12:00 A microfluidic platform for 3D cncology

    Michele Zagnoni

    Michele Zagnoni, Senior Lecturer, University Of Strathclyde
    View Bio

  • Performing drug screening of tissue derived from cancer patient biopsies using physiologically relevant 3D tumour models presents challenges due to the limited amount of available cell material
  • We have developed a microfluidic platform that enables drug screening of  multicellular spheroids derived from tumour biopsies, allowing extensive anticancer compound screening prior to treatment
  • This technology could prove a useful tool for personalised medicine and future drug development
  • 12:35 Networking Lunch

    13:35 Human induced pluripotent stem cells generate light responsive retinal organoids with variable and nutrient dependent efficiency

    Majilida Lako

    Majilida Lako, Professor of Stem Cell Science, Newcastle University
    View Bio

  • Pluripotent stem cell differentiation to 3D retinal organoids
  • Application of 3D retinal organoids for toxicology studies
  • Disease modelling with pluripotent stem cells
  • 3D retinal organoids provide a useful source of cells for photoreceptor transplantation
  • 14:10 CRACK-IT: Development of 3D eye models for early assessment of retinal toxicity

    Philip Hewitt

    Philip Hewitt, Head of Early Investigative Toxicology, Merck KGaA
    View Bio

  • What is a CRACK-IT challenge?
  • Why Establish human 3D retinal cell model: perspective from the pharmaceutical industry
  • iPSC derived multiplayer retinal models: first functional characterization – and safety testing
  • Potential use of 3D retinal models in future toxicity testing paradigms
  • 14:45 3D models for infectious diseases and vaccines

    Veronique Barban

    Veronique Barban, Expert Virology, Research and Nonclinical Safety Department , Sanofi Pasteur

  • Use of 3D-models for understanding virus mechanisms of action
  • Applications of 3D models in the vaccine industry
  • Case study: 2D and 3D liver models for yellow fever virus viscerotropism assessment
  • 15:20 Afternoon Tea

    15:50 Organoids: a patient in the lab

    Robert Vries

    Robert Vries, Managing Director, Hubrecht Institute
    View Bio

  • Patient derived adult stem cells Organoids are a clinically relevant in vitro model
  • Genetically stable, long term expanding, epithelial cultures
  • Capture patient population heterogeneity and intra patient heterogeneity
  • Use of human airway organoids for the in vitro study of hereditary, malignant or infectious pulmonary diseases
  • 16:25 Patient-derived organoids: Promises, hurdles and potential clinical applications

    Nicola Valeri

    Nicola Valeri, Team Leader, The Institute of Cancer Research
    View Bio

  • Bio-banking organoids from metastatic patients enrolled in clinical trials
  • Characterizing organoids and parental biopsies
  • Performing High-throughput screenings in 3-D
  • Co-clinical trial results: comparing responses observed in the lab with patients’ outcomes
  • 17:00 3D human induced pluripotent stem cell models of the central nervous system

    Helena Hogberg

    Helena Hogberg, Deputy Director, Center for Alternatives to Animal Testing, Johns Hopkins University Bloomberg School of Public Health

  • Characterization and overview of the 3D models
  • Functional endpoints for models of the central nervous system   
  • Application of our 3D models for toxicology
  • Application of our 3D models for disease
  • 17:35 Chairman’s Closing Remarks and Close of Day Two

    Nicola Valeri

    Nicola Valeri, Team Leader, The Institute of Cancer Research
    View Bio

    +

    FEATURED SPEAKERS

    Akidil Asli

    Akidil Asli

    Cell and Molecular Scientist , AstraZeneca
    Gary Allenby

    Gary Allenby

    Business Development Director and Chief Scientific Officer, Aurelia Bioscience
    Jason Ekert

    Jason Ekert

    Head of Complex In Vitro Models, GSK
    Nicola Valeri

    Nicola Valeri

    Team Leader, The Institute of Cancer Research
    Philip Hewitt

    Philip Hewitt

    Head of Early Investigative Toxicology, Merck KGaA
    Stefan Kustermann

    Stefan Kustermann

    Lab Head, Roche
    Stefan Przyborski

    Stefan Przyborski

    Proessor of Cell Technology, University of Durham
    Veronique Barban

    Veronique Barban

    Expert Virology, Research and Nonclinical Safety Department , Sanofi Pasteur
    William Mattes

    William Mattes

    Director, Division of Systems Biology, U.S. Food and Drug Administration

    Akidil Asli

    Cell and Molecular Scientist , AstraZeneca
    Akidil Asli

    Asli Akidil is a cell and molecular scientist within the Microphysiological Systems Centre of Excellence (MPS CoE), which is part of the Drug Safety and Metabolism(DSM) department at AstraZeneca. The MPS CoE team aims to implement both healthy and diseased-based organ-on-a-chip models for preclinical drug safety assessments and provide a platform on which early innovative drug delivery systems can be further tested. She is currently focusing on the implementation of the liver-on-a-chip platform and on the development of biomarker detection methods by employing automated confocal imaging and analysis processes.
    After graduating from Hacettepe University with a BSc in Chemistry, Asli went on to complete her MSc in Advanced Material Sciences at the University of Ulm, specialising in Biomaterials. She wrote her master’s thesis at the world-renowned Max Planck Institute for Intelligent Systems in Stuttgart, where she focused on designing in vivo like 3D platforms for both cancer and healthy cell lines.
    Upon completing of her thesis, Asli joined the Molecular Genetics for Myeloid Leukaemia clinical research group at the University Hospital of Ulm. Here, she was part of a study that performed mutation analysis in genes that are known to be involved in hematopoietic differentiation and proliferation, which result in acute myeloid leukaemia.
    She then spent three years as a researcher based in the Welcome Trust Sanger Institute and worked on collaborative projects, funded by the Medicines for Malaria Venture and Bill & Melinda Gates Foundation. The research project was to identify new anti-malarial compounds as well as define the alternations in human malaria parasites genomes that causes resistance to current drugs and treatments. To achieve this, she worked on the development of new molecular genetic approaches with CRISPR/Cas9 technology.
     

    Anne Rios

    Principal Investigator, Princess Maxima Center
    Anne Rios

    Anne Rios obtained her PhD in 2011. Her work represented a novel cell signalling mechanism that triggers the differentiation of a defined subset of cells within a stem pool (Nature, 2011). She, then joined the laboratory of Professors Visvader focusing on Breast Cancer. In 2016, she received the Medical Innovation Award (Centenary Institute Lawrence Creative Prize Winner) for her postdoctoral’s work (Nature, 2014). In 2017, she was appointed group leader at the Princess Máxima Center and head the Princess Máxima Imaging Centre. She is currently investigating the cellular mechanisms underlying pediactric and adult solid tumor progression using State-of-the-art imaging technologies.

    Gary Allenby

    Business Development Director and Chief Scientific Officer, Aurelia Bioscience
    Gary Allenby

    After completing a Ph.D. in reproductive toxicology I post-doc’ed at Hoffmann La Roche U.S.A, studying the pharmacology of retinoid biology. I returned to the U.K. into Lead Generation at Glaxo Wellcome, developing cell-based assays and working with vendors to validate new technologies for screening. In 2000 I joined Hit Identification at AstraZeneca, developing assays for respiratory and inflammatory disease and continuing to work with vendors. In 2011 I became a founding entrepreneur of Aurelia Bioscience, a pre-clinical contract research organisation specialising in the development of cell-based assays for compound and biologics screening. Our unique selling point is the development of more physiological phenotypic assays.
     

    Helena Hogberg

    Deputy Director, Center for Alternatives to Animal Testing, Johns Hopkins University Bloomberg School of Public Health
    Helena Hogberg

    Jason Ekert

    Head of Complex In Vitro Models, GSK
    Jason Ekert

    Kevin Fournier

    Sales and Applications Manager, Poietis
    Kevin Fournier

    Kevin Fournier studied medicine, cell biology and toxicology. He obtained his PhD in 2015 at the
    French School of Public Health, where he worked on cumulative impact of indoor contaminants
    on human health.During his PhD, his mentors were Andreas Kortenkamp, Bernard Jégou,
    Nathalie Bonvallot and Denis Zmirou-Navier.
    He then worked for 2 years at the French Consumer Institute as head of health and cosmetics
    departments. His works gave rise around twenty published articles that have contributed to
    changes in the consumption patterns in France.
    He is now responsible for sales and in vitro application systems at Poietis since 2018.

    Majilida Lako

    Professor of Stem Cell Science, Newcastle University
    Majilida Lako

    My research group works on human pluripotent stem cells. Our aims are to understand and define the early events occurring in human embryogenesis with special focus on eye formation and developing new treatments for eye disease. We are engaged in several large research programmes that aim to define good manufacturing protocols for deriving functional corneal and retinal cells that can be used for drug testing, disease modelling and cell based replacement therapies. Using our iPSC expertise, we have been able to establish iPSC from patients suffering from both retinitis pigmentosa and AMD and moreover we have corrected the faulty genes in these iPSC using Crispr/Cas9 technology. With the same technology we are currently targeting reporter genes to key retinal factors that control rod and cone commitment, thus enabling us to track their emergence during differentiation process and initiate studies of their transcriptome and proteome. In collaboration with Mr. Steel, we are developing new tools for delivering RPE and photoreceptors cells with high viability into degenerate retina as well as taking part in a multi-centre phase I/II clinical trial aiming at treating Stargard’t patients with hESC derived RPE cells.

    Melanie Matheu

    Founder, CEO , Prellis Biologics
    Melanie Matheu

    Michael Raghunath

    Head Center for Cell Biology & Tissue Engineering Director Competence Center TEDD, Zurich University of Applied Sciences
    Michael  Raghunath

    Michael Raghunath is a physician scientist heading the Center for Cell Biology & Tissue Engineering at the Zurich University of Applied Sciences. From 2003-2016 he was a tenured Associate Professor at the National University of Singapore (Biomedical Engineering/Biochemistry/A*STAR Institute for Medical Biology). As council member of TERMIS-EU, he is experienced in fundamental, clinical and industrial research with accomplishments in the fields of in matrix biology (pathobiochemistry of collagens and elastic microfibrils) and skin biology (wound repair, cornification disorders). He has pioneered the systematic use of macromolecular crowding as novel technology in tissue engineering to build cell-specific and lineage-directing microenvironments.

    Michele Zagnoni

    Senior Lecturer, University Of Strathclyde
    Michele Zagnoni

    Dr Michele Zagnoni leads a multidisciplinary research group focussed on the development of microfluidic technologies for healthcare applications, including fundamental biological research, drug screening, personalized medicine therapy, organ-on-a-chip and synthetic biology (www.zagnonilab.com). Recently, he became the Chief Scientific Officer of ScreenIn3D.www.screenin3d.com

    Nicola Valeri

    Team Leader, The Institute of Cancer Research
    Nicola Valeri

    Dr Valeri is a Clinician/Scientist working to discover novel therapeutic targets and novel biomarkers for gastrointestinal cancers. He leads the Gastrointestinal Cancer Biology and Genomics Team within the Centre for Molecular Pathology at the Institute of Cancer Research in London. He is also an Academic Consultant in Medical Oncology in the Gastrointestinal Cancer Unit at the Royal Marsden Hospital.
    Dr Valeri’s Team studies the biology underpinning colorectal and gastroesophageal cancer progression and resistance to treatment. His team is also working on the discovery and validation of novel bio-markers and patient-based pre-clinical models for drug discovery and development.
    Dr Valeri received several prestigious awards including the American-Italian Cancer Foundation International Fellowship, The Italian Foundation for Cancer Research Fellowship for Research Abroad, The Sidney Kimmel Translational Scholar Award and the Medical Research Society Prize at the Academy of Medical Sciences Clinician Scientist Spring Meeting. Research in Nicola’s Lab is currently funded by ICR Institutional Funding, Cancer Research UK, the European Commission Research Executive Agency and the National Institute for Health Research.
     

    Patrick Kugelmeier

    Director of Science, Kugelmeiers
    Patrick Kugelmeier

    Patrick Kugelmeier studied medicine and did his medical thesis in islet transplantation for the treatment of Diabetes. The joy of research led to an MD-PhD program for the early differentiation of stem cells. Cell culture technologies at that time didn't allow for good data reproducibility, because stem cells were cultured in 2D. Fueled by the clinical need of small, size-controlled cell clusters to improve islet transplantation and the insights from the sensitivity of stem cells, he began to develop what was later to become the Sphericalplate 5D.
    After the MD-PhD program, he did his clinical training in visceral and transplant surgery followed by trauma surgery. Besides the clinical work, the Sphericalplate 5D was further developed. Finally, it became clear that this technology opens a new dimension in cell transplantation and regenerative medicine and Dr. Kugelmeier decided to quit surgery to fully live this vision within a startup-company, the Kugelmeiers AG.
     

    Philip Hewitt

    Head of Early Investigative Toxicology, Merck KGaA
    Philip Hewitt

    I originally trained as a Medical Biochemist at the University of Birmingham (1986-1989). I worked as a Research Assistant in the Pharmacology and Toxicology Department at Imperial College, London where I received my PhD in the lab of Dr Sharon Hotchkiss. The main theme of the research project was “percutaneous absorption: metabolic and kinetic parameters”. In 1996, I transferred to The University of California, San Francisco, in the Dermatology Department; I spent 18 months there under the guidance of Prof. Howard Maibach. In 1998 I started a permanent position in the Institute of Toxicology at Merck KGaA in Germany, where I established the Molecular Toxicology Group. I am currently responsible for early cytotoxicity screening, hepatotoxicity methods, biomarker monitoring, CYP induction studies, genotoxicity testing and cytokine screening. I work with several PhD students, on external collaborative projects and I am team representative on several internal pharmaceutical projects.

    Richard Oreffo

    Director, Centre for Human Development, University Of Southampton
    Richard Oreffo

    Robert Vries

    Managing Director, Hubrecht Institute
    Robert Vries

    Robert received his PhD in Biochemistry form the Leiden University Medical Center on the study of Oncogenic cell transformation. He subsequently moved to Stanford University (USA) to do his Post Doc studying neural stem cells. Upon his return to the Netherlands he continued the study of stem cells in the group of Prof Hans Clevers at the Hubrecht Institute in The Netherlands.
    In the group of Hans Clevers he was part of the team that developed the breakthrough technology that allowed the expansion of adult stem cells. The so called Organoid Technology became the basis of the non-profit company ‘Hubrecht Organoid Technology’ (HUB) of which he is currently the managing director.

     

    Sally Price

    Head of Cell and Translational Science, Medicines Discovery Catapult
    Sally  Price

    Samuel Jackson

    Programme Manager, Disease Models, NC3Rs
    Samuel Jackson

    Dr Jackson was awarded a PhD in Neurobiology in 2004 for work studying the role of the cannabinoid system in neurodegeneration related to multiple sclerosis. During postdoctoral positions at the University of Wisconsin – Madison, UCL and QMUL, he developed and employed animal and in vitro models of demyelinating disease to probe therapeutic approaches to remyelination and neuroprotection. Following 3 years at Eli Lilly working on the neurobiology and treatment of Alzheimer’s disease, Dr Jackson left the lab to apply his knowledge of animal and alternative modelling at the NC3Rs. He is currently managing a programme of work to enable the development and uptake of human tissue based models, microphysiological systems and other alternative methods to diverse research areas, including cancer and safety pharmacology.

    Stefan Kustermann

    Lab Head, Roche
    Stefan Kustermann

    Stefan Przyborski

    Proessor of Cell Technology, University of Durham
    Stefan Przyborski

    Professor Przyborski holds an academic position as Professor in Cell Technology at Durham University. He has over 25 years experience in cell biology with specific interests in cell culture technology, neuroscience and stem cell research. In recent years he has developed a multi-disciplinary approach through collaborative projects with physical scientists to develop novel ways of solving biological problems. He has formed alliances with pharmaceutical and biotech companies, has published over 100 scientific papers and has filed several patents. He is also the founder and Chief Scientific Officer of Reinnervate (now part of ReproCELL Europe), a biotechnology company founded in 2002 as a spinout from Durham University UK. Professor Przyborski is developing new and innovative ways to manage the growth and function of cultured cells. These enabling technologies have multiple applications and will be particularly relevant to building models of human tissues to advance basic research and drug discovery.

    Veronique Barban

    Expert Virology, Research and Nonclinical Safety Department , Sanofi Pasteur
    Veronique Barban

    William Mattes

    Director, Division of Systems Biology, U.S. Food and Drug Administration
    William Mattes

    Dr. Mattes is the Director of the Division of Systems Biology, part of the FDA’s National Center for Toxicological Research. He has been an independent consultant as well as Director of Toxicology at the Critical Path Institute where he developed and directed the Predictive Safety Testing Consortium (PSTC), a collaboration of the world’s major pharmaceutical companies, with FDA and EMEA advisors. This work resulted in the establishment of a formal process of FDA/EMA biomarker qualification. Dr. Mattes also developed the COPD Biomarkers Qualification Consortium. Dr. Mattes other positions included senior scientific director of Toxicogenomics at Gene Logic, Associate Director of Toxicogenomics and Group Leader of Genetic Toxicology at Pharmacia Corp, Kalamazoo, MI, Group Leader of Experimental Toxicology and Metabolism at Ciba Pharmaceuticals, Summit, NJ, and Group Leader of Molecular and Cellular Toxicology, Ciba-Geigy Agricultural Chemical Division, Farmington, CT.

    Sponsors and Exhibitors

    Official Media Partner

    Supporters

    Workshops

    3D You Can See – Planar 3D Spheroid Arrays for Histology
    Workshop

    3D You Can See – Planar 3D Spheroid Arrays for Histology

    Copthorne Tara Hotel
    19th February 2019
    London, United Kingdom

    VENUE

    Copthorne Tara Hotel

    Scarsdale Place, Kensington, London, United Kingdom

    The Copthorne Tara Hotel London Kensington is an elegant contemporary four-star hotel in prestigious Kensington, located just a two minutes walk from High Street Kensington underground station, making exploring easy. The hotel offers well-appointed and comfortable guest rooms combining Standard, Superior and Club accommodation. Club rooms offer iconic views over the city and include Club Lounge access for complimentary breakfast and refreshments. Guests can sample the authentic Singaporean, Malaysian and Chinese cuisine at Bugis Street, traditional pub fare at the Brasserie Restaurant & Bar or relax with a delicious drink at West8 Cocktail Lounge & Bar.

    The Copthorne Tara Hotel boasts 745 square meters of flexible meeting space, consisting of the Shannon Suite and the Liffey Suite, ideal for hosting conferences, weddings and social events. Facilities include access to the business centre 24 hours a day, fully equipped fitness room, gift shop, theatre desk and Bureau de Change. With ample onsite parking outside the London congestion charge zone and excellent transport links via Heathrow Airport, the hotel is the perfect location for business or leisure stays. The hotel is within close proximity to the shops of High Street Kensington, Knightsbridge and Westfield London, Olympia Conference Centre, Royal Albert Hall, Kensington Palace and Hyde Park.

     

    HOTEL BOOKING FORM

    Sponsors and Exhibitors


    Competence Centre TEDD

    Sponsors and Exhibitors
    http://www.zhaw.ch/icbt/tedd

    Competence Centre TEDD - The first centre of its kind. The continually rising numbers of compound failures leading to early withdrawals and the increasing cost of drug development are fuelling the demand for biologically more complex cell models. Here, physiological relevance is key for improving the predictive power of cell-based assays. 3D cell culture technology, organ-like tissue models and associated analytical tools are essential for basic and pharmaceutical research as well as for the evaluation of chemicals and cosmetics. The TEDD Competence Centre is a collaborative innovation platform, dedicated to 3D cell culture technology and organ-like tissue models for drug development, substance testing, personalized and regenerative medicine. Thus, TEDD also promotes the 3R of animal welfare with a particular emphasis on the third R, replace. As an information and matchmaking hub, TEDD transfers knowledge and technologies in order to promote the development and application of 3D cell culture. The TEDD community is currently composed of partners from academia, clinical medicine and industry. The industrial partners represent the majority of TEDD partners and comprise a spectrum from young spin-off company to world player. Thus, TEDD represents the entire value chain of biotech R&D relevant for 3D tissue engineering, be it ultra flat 3D monolayer culture, bioprinted tissue constructs, or organoids.


    InoCure

    Sponsors and Exhibitors
    http://www.inocure.cz

    InoCure s.r.o. is a SME focused on development of advanced nanomaterials for life science use. We are developing drug delivery and scaffolding systems based on nano/microparticles (µSphere technology) and nanofibrous systems (InoMATRIX technology). InoCure helps its partners design next generation of drug delivery systems and introduce those into mass production.

    Media Partners


    Biocompare

    Official Media Partner
    http://www.biocompare.com

    Biocompare.com is the leading resource for up-to-date product information, product reviews, and new technologies for life scientists. Biocompare combines an in-depth knowledge of life science products and new technologies with the power of the Internet to offer scientists the most dynamic, relevant, and innovative media-based marketplace for life science information.


    Drug Target Review

    Official Media Partner
    http://www.drugtargetreview.com

    Drug Target Review’s quarterly magazine, website and annual events program provides high quality content with peer-written articles that are submitted exclusively by the world’s most respected scientists in their field. This attracts a committed base of readers, users and delegates made up of senior decision-makers from the life science and drug discovery industries at the top pharmaceutical companies, as well as academics and scientists from the top research institutes across the globe.


    Drug Discovery Today

    Official Media Partner
    http://www.drugdiscoverytoday.com/

    Drug Discovery Today is one of the most cited review journals in the field of drug discovery, with an impact factor of 6.422.
    Drug Discovery Today will benefit your research by helping to keep you up-to-date with all of the fast-moving and emerging topics in drug discovery. Each issue is packed full of the latest research news, peer-reviewed articles and comment and opinion from leading research scientists.


    Labiotech.eu

    Official Media Partner
    https://goo.gl/DRE2Gp

    Labiotech.eu is the leading digital media covering the European Biotech industry. Over 100,000 monthly visitors use it to keep an eye on the business and innovations in biotechnology. Hope you'll enjoy reading our stories!

    Media Partners


    Mednous

    Supporters
    http://www.MedNous.com

    MedNous is a print publication and website about medical innovation in Europe. It carries exclusive interviews with companies that are at the forefront of medical technology, as well as contributor articles from prominent practitioners. Our mission is to identify significant advances in medicine and to explain how this innovation is being commercialised. In doing so, we talk to venture capitalists about what products and platforms they are supporting. We report on how regulators cope with the accelerating pace of innovation. And we regularly cover the latest developments in the discovery and development of new medical concepts in the area of antibodies, vaccines, small molecules, regenerative medicine and nanomedicines. MedNous combines the English word for medicine with the Greek word for intellect. And those with nous are readers of our publication. Visit our website: www.mednous.com


    Pharmalicensing

    Supporters
    http://www.pharmalicensing.com

    Pharmalicensing (www.pharmalicensing.com) is the premier biopharmaceutical Open Innovation resource designed for professionals involved with partnering, licensing and business development worldwide. Actively supporting all forms of partnering and in- and out-licensing activities, Pharmalicensing utilizes the unique online Showcase Profiling & Discover services, as well as its renowned Partnering Search service leveraging its global network of industry experts, to enable companies to identify and engage with appropriate partners around the world. Pharmalicensing is actively utilized by many tens of thousands of industry professionals each month. Pharmalicensing is a division of Cognis Group, Inc.


    Gate2Biotech

    Supporters
    http://www.gate2biotech.com

    Gate2Biotech is a portal that unites biotechnological community in Central Europe. It covers all the news in the field of biotechnology. Thanks to the the portal the companies engaged in the field can easily search for research institutions and other partners to solve technical problems they are facing and here they can also present their services offer to potential partners from the Czech Republic and abroad. Gate2Biotech portal serves as a bridge connecting scientific and commercial sector. It incorporates offices and support organizations dedicated to promoting transfer of innovative technologies into a unified communication platform of Czech and international biotechnologies. As a mediator of information it draws attention to biotechnologies and support of their application and transfer into practice. It also functions as a tool for encouraging non-professionals (especially scientists and students) towards innovative business or applied research.


    CanBiotech

    Supporters
    http://www.canbiotech.com

    CanBiotech - A Portal and B2B Outsourcing Marketplace for the Biotech and Pharmaceutical Industry. The Marketplace features the Outsourcing Services Showcase; the Portal features our biopharmaceutical and venture capital directories and databases. Publications include the BioMedical Outsourcing Report and the Bio Outsourcing Asia© Publication.


    Bentham Science

    Supporters
    http://www.benthamscience.com/

    Bentham Science Publishers is a major STM journal publisher of 130 plus print and online journal. Out of these, 40 journals have already registered good IMPACT FACTORS as per Journal Citation Reports® 2017. These titles have extensive readership mostly in Europe and North America. For a detailed profile please visit our website at http://www.benthamscience.com. Besides, Bentham Science publishes eBooks in all areas of Science, Technology and Medicine. Our eBooks provide professionals, academicians, corporate researchers, graduates and undergraduates worldwide with the most current information in their subject areas of interest. Our eBooks are also available in the ePub and Kindle formats besides the PDF edition here http://ebooks.benthamscience.com/. Bentham is offering attendees of this conference discounts on its publication. For more information click here


    Swiss Biotech Association

    Supporters
    http://www.swissbiotech.org/

    The Swiss Biotech Association (SBA) is the national industry association for biotechnology, including pharmaceuticals, diagnostics, agriculture, food, cosmetics, environmental biotechnology, and specialty chemicals. Members are companies active in modern biotechnology, such as R&D, Production, Marketing and Sales, Finance, Services and Consulting. SBA provides a networking platform for Life Science clusters, academic and federal institutions the like. Founded in March 1998, the Association grows steadily.


    Drug Development Technology

    Supporters
    http://www.drugdevelopment-technology.com

    Drugdevelopment-technology.com covers every aspect of the drug development and research process, from conception to pre-FDA approval. Our global network of journalists updates the site with the latest and most significant industry developments. This coverage allows us to provide everyone - from senior management through to research and QA staff – with in-depth reviews of the latest projects, advance notice of new product releases and analysis of the latest procedural and legislative developments.


    Technology Networks

    Supporters
    http://go.technologynetworks.com/subscribe-to-newsletters

    Founded in 2000, Technology Networks is established as the leading news provider for life science and drug discovery professionals. In addition, we provide unique content including webcasts, videos, application notes and posters from recent conferences. Our portfolio now includes around 30 focussed scientific communities, all of which are accessible free of charge within TechnologyNetworks.com

    SAVE TO


    Outlook Calendar  OUTLOOK CALENDAR
    Google Calendar  GOOGLE CALENDAR
    ICal Calendar  ICAL CALENDAR
    Yahoo! Calendar  YAHOO! CALENDAR

    Copthorne Tara Hotel

    Scarsdale Place
    Kensington
    London W8 5SR
    United Kingdom

    Copthorne Tara Hotel

    The Copthorne Tara Hotel London Kensington is an elegant contemporary four-star hotel in prestigious Kensington, located just a two minutes walk from High Street Kensington underground station, making exploring easy. The hotel offers well-appointed and comfortable guest rooms combining Standard, Superior and Club accommodation. Club rooms offer iconic views over the city and include Club Lounge access for complimentary breakfast and refreshments. Guests can sample the authentic Singaporean, Malaysian and Chinese cuisine at Bugis Street, traditional pub fare at the Brasserie Restaurant & Bar or relax with a delicious drink at West8 Cocktail Lounge & Bar.

    The Copthorne Tara Hotel boasts 745 square meters of flexible meeting space, consisting of the Shannon Suite and the Liffey Suite, ideal for hosting conferences, weddings and social events. Facilities include access to the business centre 24 hours a day, fully equipped fitness room, gift shop, theatre desk and Bureau de Change. With ample onsite parking outside the London congestion charge zone and excellent transport links via Heathrow Airport, the hotel is the perfect location for business or leisure stays. The hotel is within close proximity to the shops of High Street Kensington, Knightsbridge and Westfield London, Olympia Conference Centre, Royal Albert Hall, Kensington Palace and Hyde Park.

     

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.

    Thank you for visiting our event

    If you would like to receive further information about our events, please fill out the information below.

    By ticking above you are consenting to receive information by email from SMi.
    Full details of our privacy policy can be found here https://www.smi-online.co.uk/privacy-legals/privacy-policy/.
    Should you wish to update your contact preferences at any time you can contact us at data@smi-online.co.uk.
    Should you wish to be removed from any future mailing lists please click on the following link http://www.smi-online.co.uk/opt-out